PH20946A - Pyridine derivatives and their production - Google Patents

Pyridine derivatives and their production

Info

Publication number
PH20946A
PH20946A PH32628A PH32628A PH20946A PH 20946 A PH20946 A PH 20946A PH 32628 A PH32628 A PH 32628A PH 32628 A PH32628 A PH 32628A PH 20946 A PH20946 A PH 20946A
Authority
PH
Philippines
Prior art keywords
production
pyridine derivatives
pyridine
derivatives
Prior art date
Application number
PH32628A
Other languages
English (en)
Inventor
Hohara Akida
Maki Yoshitaka
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15916456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH20946(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PH20946A publication Critical patent/PH20946A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PH32628A 1984-08-16 1985-08-13 Pyridine derivatives and their production PH20946A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59171069A JPS6150978A (ja) 1984-08-16 1984-08-16 ピリジン誘導体およびその製造法

Publications (1)

Publication Number Publication Date
PH20946A true PH20946A (en) 1987-06-10

Family

ID=15916456

Family Applications (1)

Application Number Title Priority Date Filing Date
PH32628A PH20946A (en) 1984-08-16 1985-08-13 Pyridine derivatives and their production

Country Status (23)

Country Link
US (2) US4628098A (ca)
EP (1) EP0174726B1 (ca)
JP (1) JPS6150978A (ca)
KR (1) KR920002128B1 (ca)
AU (1) AU570130B2 (ca)
BG (1) BG60415B2 (ca)
CA (1) CA1255314A (ca)
DE (3) DE19975020I2 (ca)
DK (1) DK171340B1 (ca)
ES (1) ES8607288A1 (ca)
GE (1) GEP19960313B (ca)
GR (1) GR851981B (ca)
HK (1) HK4792A (ca)
HU (1) HU195210B (ca)
IE (1) IE58363B1 (ca)
MX (1) MX9203043A (ca)
NL (1) NL930109I2 (ca)
NO (2) NO163131C (ca)
PH (1) PH20946A (ca)
SG (1) SG103291G (ca)
SU (1) SU1507211A3 (ca)
UA (1) UA7140A1 (ca)
ZA (1) ZA856117B (ca)

Families Citing this family (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174717B1 (en) 1984-07-06 1992-01-22 FISONS plc Benzimidazoles, and their production formulation and use as gastric acid secretion inhibitors
US6749864B2 (en) * 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1276017C (en) * 1986-02-13 1990-11-06 Takeda Chemical Industries, Ltd. Sulfenamide derivatives and their production
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
JPH03504497A (ja) * 1988-05-25 1991-10-03 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 新規フルオルアルコキシ化合物
US5223515A (en) * 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
JP2536173B2 (ja) * 1988-08-18 1996-09-18 武田薬品工業株式会社 注射剤
AT391693B (de) * 1988-11-15 1990-11-12 Cl Pharma Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
SE8804628D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New compounds
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
IE64199B1 (en) * 1988-12-22 1995-07-12 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
ES2066120T3 (es) * 1989-02-10 1995-03-01 Takeda Chemical Industries Ltd Uso de derivados de bencimidazol como agentes antibacterianos.
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5274099A (en) * 1989-12-20 1993-12-28 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
CA2053527C (en) * 1990-10-17 2002-03-12 Takashi Sohda Pyridine derivatives, their production and use
TW209174B (ca) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
ES2036948B1 (es) * 1991-11-21 1994-09-01 Genesis Para La Investigacion Procedimiento de obtencion de compuestos derivados de piridina.
CA2138787A1 (en) * 1992-07-08 1994-01-20 Clifton Augustus Baile Alleviating stomach ulcers in swine
US5589491A (en) * 1992-07-28 1996-12-31 Astra Aktiebolag Injection and injection kit containing omeprazole and its analogs
WO1994019346A1 (de) * 1993-02-17 1994-09-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituierte heteroarylalkylthiopyridine zur bekämpfung von helicobacter bakterien
ES2060541B1 (es) * 1993-02-26 1995-11-16 Vinas Lab Nuevo procedimiento para la sintesis de un derivado de 2-(2-piridilmetilsufinil) bencimidazol, y nuevos productos intermedios obtenidos con el mismo.
ES2063705B1 (es) * 1993-06-14 1995-07-16 S A L V A T Lab Sa Intermedio para la sintesis de lansoprazol y su procedimiento de obtencion.
JPH08512037A (ja) * 1993-06-29 1996-12-17 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換されたアリールチオアルキルチオピリジン
TW280770B (ca) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
US5502195A (en) * 1993-11-04 1996-03-26 Slemon; Clarke Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
CN1048980C (zh) * 1994-03-29 2000-02-02 广东汕头鮀滨化学药业总公司 一种新的吡啶衍生物及其制备方法和应用
AU698249B2 (en) * 1994-06-10 1998-10-29 Altana Pharma Ag Thiopyridines for combating (helicobacter) bacteria
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
ES2236628T3 (es) * 1995-09-21 2005-07-16 Pharma Pass Ii Llc Composicion farmaceutica que contiene un omeprazol labil de acido, y procedimiento para su preparacion.
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6599927B2 (en) 1996-10-11 2003-07-29 Astrazeneca Ab Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP2002510293A (ja) * 1997-05-30 2002-04-02 ドクター・レディーズ・リサーチ・ファウンデーション 抗潰瘍剤として新規なベンゾイミダゾール誘導体、それらの製造方法、及びそれらを含有する薬学的組成物
WO1999004816A1 (en) 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
EP2263660B1 (en) 1998-05-18 2017-09-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
WO2000000474A1 (en) * 1998-06-26 2000-01-06 Russinsky Limited Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds
SI20019A (sl) * 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
AU763642B2 (en) * 1998-07-22 2003-07-31 Sepracor, Inc. Pharmaceutical compositions comprising hydroxylansoprazole and uses thereof
BR9912937A (pt) * 1998-08-10 2001-05-08 Partnership Of Michael E Garst Pró-drogas de inibidores de bomba de prótons
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
ES2262335T3 (es) 1998-08-12 2006-11-16 Altana Pharma Ag Forma de administracion oral para piridin-2-ilmetilsulfinil-1h-bencimidazoles.
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
YU86001A (sh) 1999-06-07 2004-07-15 Altana Pharma Ag. Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
WO2001002389A1 (en) * 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
KR100359256B1 (ko) * 1999-10-06 2002-11-04 한미약품공업 주식회사 란소프라졸의 개선된 제조방법
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
ES2171116B1 (es) * 2000-04-14 2003-08-01 Esteve Quimica Sa Procedimiento para la obtencion de derivados de (((piridil sustituido)metil)tio)bencimidazol.
EP1897877B1 (en) 2000-05-15 2014-09-24 Takeda Pharmaceutical Company Limited Crystalline forms of (R)-lanzoprazole
ATE342263T1 (de) 2000-08-04 2006-11-15 Takeda Pharmaceutical Salze von benzimidazol-derivaten und deren verwendung
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
CA2436825C (en) * 2000-12-01 2011-01-18 Takeda Chemical Industries, Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
JP4241041B2 (ja) 2000-12-07 2009-03-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸分解性活性成分を含有するペースト形の医薬品製造物
AU2002234545A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
SI1341528T1 (sl) 2000-12-07 2012-05-31 Nycomed Gmbh Hitro razpadljiva tableta ki obsega kislinsko labilno aktivno sestavino
KR100430575B1 (ko) * 2001-02-21 2004-05-10 주식회사 씨트리 란소프라졸 및 그 중간체의 제조방법
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
KR20040025677A (ko) * 2001-09-18 2004-03-24 제리아 신야쿠 고교 가부시키 가이샤 벤즈이미다졸 유도체
US20040248941A1 (en) * 2001-09-25 2004-12-09 Keiji Kamiyama Benzimidazone compound, process for producing the same, and use thereof
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ES2392960T3 (es) 2001-10-17 2012-12-17 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
SE0104295D0 (sv) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
RU2215739C1 (ru) * 2002-04-03 2003-11-10 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Способ получения 5-метокси-2-(4-метокси-3,5-диметил-2-пиридилметилтио)бензимидазола
JP4698950B2 (ja) 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
KR100873419B1 (ko) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
BR0312802A (pt) * 2002-07-19 2005-04-19 Michael E Garst Pró-drogas de inibidores de bombas de próton
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
JP4634144B2 (ja) * 2002-08-01 2011-02-16 ニコックス エスエー ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
ATE375338T1 (de) * 2002-08-21 2007-10-15 Teva Pharma Verfahren zur aufreinigung von lanzoprazol
ATE472329T1 (de) 2002-08-30 2010-07-15 Nycomed Gmbh Verwendung der kombination von ciclesonid und antihistaminika zur behandlung von allergischer rhinitis
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
CA2771725C (en) 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP1743893A1 (en) 2002-11-18 2007-01-17 Teva Pharmaceutical Industries Ltd. Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
ES2237354T3 (es) * 2002-11-18 2007-11-01 Teva Pharmaceutical Industries Ltd. Lansoprazol estable que contiene mas de 500 ppm, hasta aproximadamente 3.000 ppm de agua y mas de 200 ppm, hasta aproximadamente 5.000 ppm de alcohol.
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
US7452998B2 (en) 2002-12-06 2008-11-18 Nycomed Gmbh Process for preparing optically pure active compounds
ATE553103T1 (de) 2002-12-06 2012-04-15 Nycomed Gmbh Verfahren zur herstellung von (s)-pantoprazol
WO2004056804A2 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
JP2006516574A (ja) * 2003-02-05 2006-07-06 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール安定化方法
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1601667A2 (en) * 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline and amorphous solids of pantoprazole and processes for their preparation
US8449911B2 (en) 2003-03-12 2013-05-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
US7608625B2 (en) * 2003-03-13 2009-10-27 Eisai R & D Management Co., Ltd. Method for treating bruxism and bruxism-related diseases
US20050031696A1 (en) * 2003-04-22 2005-02-10 Dr. Reddy's Laboratories Limited Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
CA2528993A1 (en) * 2003-06-10 2004-12-23 Teva Pharmaceutical Industries Ltd. Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
MXPA06000410A (es) * 2003-07-15 2006-03-17 Allergan Inc Procedimiento para preparar profarmacos isomericamente puros de inhibidores de la bomba de protones.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060241037A1 (en) * 2003-10-03 2006-10-26 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
AU2005216862A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
WO2005082338A2 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Prodrugs for the intravenous administration of proton pump inhibitors
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
AU2005249367A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
EP1742946A1 (en) * 2004-04-28 2007-01-17 Altana Pharma AG Dialkoxy-imidazopyridines derivatives
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
JP5173191B2 (ja) 2004-09-13 2013-03-27 武田薬品工業株式会社 酸化化合物の製造方法及び製造装置
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006053383A1 (en) 2004-11-22 2006-05-26 Anadis Ltd Bioactive compositions
EP1681056A1 (en) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
EP1852100B1 (en) 2005-02-25 2018-05-09 Takeda Pharmaceutical Company Limited Method for producing coated granules of a benzimidazole compound
KR100771659B1 (ko) 2005-03-23 2007-10-30 주식회사 카이로제닉스 판토프라졸 및 그 중간체의 제조방법
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
EP1889841A4 (en) 2005-06-07 2010-04-07 Takeda Pharmaceutical CRYSTAL OF A SALT OF A BENZIMIDAZOLE COMPOUND
CA2611917A1 (en) * 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited Injection
US7601737B2 (en) 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5053865B2 (ja) 2005-12-28 2012-10-24 武田薬品工業株式会社 口腔内崩壊性固形製剤の製造法
CN101389316A (zh) 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
ATE533757T1 (de) * 2006-03-10 2011-12-15 Arigen Pharmaceuticals Inc Neues pyridinderivat mit wirkung gegen helicobacter pylori
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
US8129536B2 (en) * 2006-09-22 2012-03-06 Orchid Chemicals & Pharmaceuticals Limited Method for the purification of lansoprazole
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
NZ598728A (en) 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2008081891A1 (ja) 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤
WO2008087665A2 (en) * 2007-01-18 2008-07-24 Matrix Laboratories Ltd Process for preparation of lansoprazole
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
TW200840574A (en) * 2007-04-02 2008-10-16 Univ Nat Taiwan The pharmaceutical component for treating hearing loss disease
US20100210847A1 (en) * 2007-07-17 2010-08-19 Ranbaxy Laboratories Limited Process for the preparation of pantoprazole sodium and pantoprazole sodium sesquihydrate
KR20100116165A (ko) 2007-10-12 2010-10-29 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
WO2009087672A1 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole
US20100286400A1 (en) 2007-12-31 2010-11-11 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US20090227633A1 (en) * 2008-03-04 2009-09-10 Bassam Damaj Methods to inhibit tumor cell growth by using proton pump inhibitors
UA103189C2 (ru) 2008-03-10 2013-09-25 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма бензимидазольного соединения
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
WO2010079504A2 (en) 2008-05-14 2010-07-15 Watson Pharma Private Limited Stable r(+)-lansoprazole amine salt and a process for preparing the same
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
CA2740095A1 (en) * 2008-10-10 2010-04-15 Celtaxsys, Inc. Method of inducing negative chemotaxis
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
WO2011138797A2 (en) 2010-05-04 2011-11-10 Cadila Healthcare Limited Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
MX2013006247A (es) 2010-12-03 2014-01-31 Takeda Pharmaceutical Tableta oralmente desintegradora.
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2014501224A (ja) 2010-12-27 2014-01-20 武田薬品工業株式会社 口腔内崩壊錠
US9233103B2 (en) 2011-03-25 2016-01-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
CA2857457C (en) 2011-11-30 2018-05-01 Takeda Pharmaceutical Company Limited Dry coated tablet
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
WO2013108068A1 (en) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers
MX383752B (es) 2013-01-15 2025-03-11 Ironwood Pharmaceuticals Inc Forma de dosificación oral de liberación sostenida gastro retentiva de un secuestrante de ácido biliar.
HK1221899A1 (en) 2013-05-21 2017-06-16 Takeda Pharmaceutical Company Limited Oral disintegrating tablets
US9457011B2 (en) 2014-02-25 2016-10-04 Muslim D. Shahid Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
CN107365300B (zh) * 2017-07-26 2019-08-02 桂林华信制药有限公司 一种有效去除兰索拉唑粗品中杂质的方法
EP3824296A4 (en) 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE
CN114163419A (zh) * 2021-12-24 2022-03-11 辰欣药业股份有限公司 一种兰索拉唑的制备方法
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
ZA825106B (en) * 1981-08-13 1983-04-27 Haessle Ab Novel pharmaceutical compositions
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
IL71664A (en) * 1983-05-03 1987-11-30 Byk Gulden Lomberg Chem Fab Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same
US4575554A (en) * 1983-12-05 1986-03-11 The Upjohn Company Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB8417171D0 (en) * 1984-07-05 1984-08-08 Beecham Group Plc Compounds
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds

Also Published As

Publication number Publication date
CA1255314A (en) 1989-06-06
NO1995002I1 (no) 1995-03-31
DE19975017I2 (de) 2009-08-06
KR920002128B1 (ko) 1992-03-12
HU195210B (en) 1988-04-28
ZA856117B (en) 1986-04-30
BG60415B2 (bg) 1995-02-28
DE19975020I2 (de) 2009-08-06
NO853226L (no) 1986-02-17
JPS6150978A (ja) 1986-03-13
US4628098A (en) 1986-12-09
EP0174726B1 (en) 1989-04-26
ES546152A0 (es) 1986-05-16
GR851981B (ca) 1985-12-16
US4689333A (en) 1987-08-25
UA7140A1 (uk) 1995-06-30
SU1507211A3 (ru) 1989-09-07
SG103291G (en) 1993-02-19
AU570130B2 (en) 1988-03-03
DK356485A (da) 1986-02-17
IE58363B1 (en) 1993-09-08
NL930109I2 (nl) 1997-02-03
MX9203043A (es) 1992-07-01
DK171340B1 (da) 1996-09-16
IE851976L (en) 1986-02-16
HK4792A (en) 1992-01-17
GEP19960313B (en) 1996-06-24
EP0174726A1 (en) 1986-03-19
NO163131B (no) 1990-01-02
HUT39444A (en) 1986-09-29
NL930109I1 (nl) 1993-10-18
JPH0244473B2 (ca) 1990-10-04
DK356485D0 (da) 1985-08-06
AU4589585A (en) 1986-02-20
NO163131C (no) 1994-10-24
ES8607288A1 (es) 1986-05-16
KR870002125A (ko) 1987-03-30
DE3569736D1 (en) 1989-06-01

Similar Documents

Publication Publication Date Title
DE3569736D1 (en) Pyridine derivatives and their production
AU1018388A (en) Novel pyridine derivatives and processes for their production
PT80892A (en) Quinone derivatives their production and use
GB8402740D0 (en) Furo-(3 4-c)-pyridine derivatives
EP0157609A3 (en) Lipid derivatives their production and use
DE3568435D1 (en) 2-acetoacetylglycerol derivatives, their production and use
DE3574133D1 (en) Norbornyl pyridine derivatives, their production and compositions comprising them
PT83059A (en) Pyridine derivatives process for their production and herbicidal composition
GB2181729B (en) Glucosylmoranoline derivatives and production thereof
AR242212A1 (es) Un proceso para la preparacion de nuevos derivados de 1,3-dihidro-6-¡1- ciano-1-isopropil-n-fenetil-n-metil-omega-aminoalquil-7-hidro xi-furo-(3,4c)-piridina
GB8422461D0 (en) Pyridine derivatives
GB8426738D0 (en) Pyridine derivatives
EP0178909A3 (en) Guanidylfungin derivatives and their production
EP0226896A3 (en) Lankacidin derivatives and production thereof
EP0271829A3 (en) Delta-hydroxy-beta-lysine derivatives and their production
ZA859034B (en) Imidazolylethoxyindanic derivatives and process for their production
DE3473876D1 (en) Benzopyran-4-on derivatives and their production
EP0177272A3 (en) Manufacture of pyridine
GB8520007D0 (en) Pyridine derivatives
GB8507008D0 (en) Pyridine derivatives
GB8521304D0 (en) Pyridine derivatives
GB8520169D0 (en) Pyridine derivatives
DE3261765D1 (en) Aminonaphthacene derivatives and their production
GB8524110D0 (en) Pyridine
GB2162180B (en) Pyridone derivatives